

1. **Interventional Psychiatry and Brain Stimulation Subspecialties:** [1], [2], [3], [4], [5], [6]
2. **Disease Burden:** [7], [8]
3. **STAR*D:** [9], [10], [11]
4. **The Bell Jar:** [12], [1], [13]
5. **Historical Context on Brain Stimulation:** [14], [15]
6. **Major TMS Trials:** [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27]
7. **TMS Meta-Analyses:** [28], [29]
8. **TMS Naturalistic Outcomes and Data Registries:** [30], [31], [32]
9. **TMS Durability:** [33]
10. **TMS Consensus Statements:** [34], [35], [36]
11. **TMS Safety Guidelines:** [37], [38],
12. **TMS Targeting:** [39], [40], [41], [42], [43], [44], [45], [46], [47]
13. **NOVA Science Now: Magnetic Mind Control:** <https://www.pbs.org/video/nova-sciencenow-magnetic-mind-control/>

Reference List

1. Taylor, J.J., H. Kober, and D.A. Ross, *The Electrochemical Brain: Lessons From The Bell Jar and Interventional Psychiatry*. Biol Psychiatry, 2018. **84**(3): p. e23-e24.
2. Williams, N., *Interventional psychiatry: planning for core competency across the psychiatry milestone spectrum*.
3. Williams, N.R., et al., *Interventional psychiatry: why now?* J Clin Psychiatry, 2014. **75**(8): p. 895-7.
4. Williams, N.R., et al., *Interventional psychiatry: how should psychiatric educators incorporate neuromodulation into training?* Acad Psychiatry, 2014. **38**(2): p. 168-76.
5. Nikayin, S., J.J. Taylor, and R.B. Ostroff, *Advanced training in interventional psychiatry*. J Neurol Sci, 2022. **434**: p. 120093.
6. Siddiqi, S.H., et al., *Towards accredited clinical training in brain stimulation: Proceedings from the Brain Stimulation Subspecialty Summits*. Brain Stimul, 2025.
7. DALYs, G.B.D., et al., *Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition*. Lancet, 2015. **386**(10009): p. 2145-91.
8. Whiteford, H.A., et al., *Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010*. Lancet, 2013. **382**(9904): p. 1575-86.
9. Rush, A.J., et al., *Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report*. Am J Psychiatry, 2006. **163**(11): p. 1905-17.
10. Rush, A.J., *Combining antidepressant medications: a good idea?* Am J Psychiatry, 2010. **167**(3): p. 241-3.

11. Rush, A.J., *Star-D: lessons learned and future implications*. *Depress Anxiety*, 2011. **28**(7): p. 521-4.
12. Plath, S., *The Bell Jar*. 2005: Harper Perennial Modern Classics.
13. Bergsholm, P., *Sylvia Plath Recovered Completely by Electroconvulsive Therapy at the Age of 21 Years and Might Have Been Saved by Another Series 9 Years Later*. *J ECT*, 2017. **33**(3): p. e26.
14. Merton, P.A. and H.B. Morton, *Stimulation of the cerebral cortex in the intact human subject*. *Nature*, 1980. **285**(5762): p. 227.
15. Barker, A.T., R. Jalinous, and I.L. Freeston, *Non-invasive magnetic stimulation of human motor cortex*. *Lancet*, 1985. **1**(8437): p. 1106-7.
16. O'Reardon, J.P., et al., *Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial*. *Biol Psychiatry*, 2007. **62**(11): p. 1208-16.
17. O'Reardon, J.P., et al., *Reply regarding "efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial"*. *Biol Psychiatry*, 2010. **67**(2): p. e15-7.
18. George, M.S., et al., *Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial*. *Archives of general psychiatry*, 2010. **67**(5): p. 507-16.
19. Levkovitz, Y., et al., *Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial*. *World Psychiatry*, 2015. **14**(1): p. 64-73.
20. Yesavage, J.A., et al., *Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial*. *JAMA Psychiatry*, 2018. **75**(9): p. 884-893.
21. Papakostas, G.I., et al., *Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial*. *Mol Psychiatry*, 2024.
22. Blumberger, D.M., et al., *Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial*. *Lancet*, 2018. **391**(10131): p. 1683-1692.
23. Cole, E.J., et al., *Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression*. *Am J Psychiatry*, 2020. **177**(8): p. 716-726.
24. Cole, E.J., et al., *Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial*. *Am J Psychiatry*, 2021: p. appiajp202120101429.
25. Carmi, L., et al., *Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial*. *Am J Psychiatry*, 2019: p. appiajp201918101180.
26. Zangen, A., et al., *Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial*. *World Psychiatry*, 2021. **20**(3): p. 397-404.
27. Yip, A.G., et al., *61% of unmedicated treatment resistant depression patients who did not respond to acute TMS treatment responded after four weeks of twice weekly deep TMS in the Brainsway pivotal trial*. *Brain Stimul*, 2017. **10**(4): p. 847-849.

28. Berlim, M.T., et al., *Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials*. Psychol Med, 2014. **44**(2): p. 225-39.
29. Berlim, M.T., et al., *Efficacy of theta burst stimulation (TBS) for major depression: An exploratory meta-analysis of randomized and sham-controlled trials*. J Psychiatr Res, 2017. **90**: p. 102-109.
30. Sackeim, H.A., et al., *Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation*. J Affect Disord, 2020. **277**: p. 65-74.
31. Carpenter, L.L., et al., *Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice*. Depress Anxiety, 2012. **29**(7): p. 587-96.
32. Hutton, T.M., et al., *Dosing transcranial magnetic stimulation in major depressive disorder: Relations between number of treatment sessions and effectiveness in a large patient registry*. Brain Stimul, 2023. **16**(5): p. 1510-1521.
33. Dunner, D.L., et al., *A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period*. J Clin Psychiatry, 2014. **75**(12): p. 1394-401.
34. McClintock, S.M., et al., *Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression*. J Clin Psychiatry, 2018. **79**(1).
35. Perera, T., et al., *The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder*. Brain Stimul, 2016. **9**(3): p. 336-46.
36. Trapp, N.T., et al., *Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology*. Clin Neurophysiol, 2024. **170**: p. 206-233.
37. Rossi, S., et al., *Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research*. Clin Neurophysiol, 2009. **120**(12): p. 2008-39.
38. Rossi, S., et al., *Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines*. Clinical Neurophysiology, 2020.
39. Cash, R.F.H., et al., *Using Brain Imaging to Improve Spatial Targeting of Transcranial Magnetic Stimulation for Depression*. Biol Psychiatry, 2021. **90**(10): p. 689-700.
40. Cash, R.F.H., et al., *Personalized connectivity-guided DLPFC-TMS for depression: Advancing computational feasibility, precision and reproducibility*. Hum Brain Mapp, 2021. **42**(13): p. 4155-4172.
41. Cash, R.F.H., et al., *Subgenual Functional Connectivity Predicts Antidepressant Treatment Response to Transcranial Magnetic Stimulation: Independent Validation and Evaluation of Personalization*. Biol Psychiatry, 2019. **86**(2): p. e5-e7.

42. Trapp, N.T., et al., *Reliability of targeting methods in TMS for depression: Beam F3 vs. 5.5 cm*. Brain Stimul, 2020. **13**(3): p. 578-581.
43. Trapp, N.T., et al., *A randomized trial comparing beam F3 and 5.5 cm targeting in rTMS treatment of depression demonstrates similar effectiveness*. Brain Stimul, 2023. **16**(5): p. 1392-1400.
44. Fox, M.D., H. Liu, and A. Pascual-Leone, *Identification of reproducible individualized targets for treatment of depression with TMS based on intrinsic connectivity*. Neuroimage, 2013. **66**: p. 151-60.
45. Fox, M.D., et al., *Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate*. Biol Psychiatry, 2012. **72**(7): p. 595-603.
46. ESA, D., et al., *Probing prefrontal-sgACC connectivity using TMS-induced heart-brain coupling*. Nature Mental Health, 2024. **2**: p. 809-817.
47. Taylor, J.J., et al., *Symptom-specific brain circuit stimulation: A head-to-head randomized trial*. PREPRINT (Version 1) available at Research Square 2024.